Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has achieved revenue and profit growth in the first half of 2025, driven by the sales of its A-type recombinant human collagen products and the approval of new gel products [5][6] - The company is expanding its sales channels, with its "Wei Yi Mei" brand products covering over 4,000 medical institutions [5][6] - The company plans to raise 2 billion RMB through a private placement to enhance its research and development capabilities and expand its product offerings [5][7] Summary by Sections Market Performance - The closing price as of August 25, 2025, is 316.46 RMB, with a market capitalization of 36,413.58 million RMB [3] Financial Performance - Revenue has grown from 161 million RMB in 2020 to 1.443 billion RMB in 2024, with a compound annual growth rate (CAGR) of 72.9% [6][12] - The net profit attributable to the parent company reached 732 million RMB in 2024, with a CAGR of 118.8% from 2020 to 2024 [6][12] - In the first half of 2025, the company reported revenue of 859 million RMB, a year-on-year increase of 42.43%, and a net profit of 392 million RMB, up 26.65% year-on-year [6][12] Product Development and Market Strategy - The company has received regulatory approval for its "Injection of Recombinant Type III Humanized Collagen Gel," which is expected to enhance its product lineup [5][19] - The company is focusing on expanding its international presence, having obtained medical device registration in Thailand and certifications in the USA and Saudi Arabia for its functional skincare products [5][19] - The company is collaborating with strategic investor Yangsheng Tang to enhance its R&D and commercialization efforts [7][24] Future Outlook - The company forecasts net profits of 1.018 billion RMB, 1.410 billion RMB, and 1.833 billion RMB for 2025, 2026, and 2027, respectively, with corresponding price-to-earnings ratios of 36, 26, and 20 times [7][8] - The company aims to leverage its technological advancements in collagen products to capture a larger market share in the medical aesthetics and functional skincare sectors [5][9]

证券研究报告 电子 | 半导体 非金融|公司点评报告 hyzqdatemark 2025 年 08 月 26 日 证券分析师 葛星甫 SAC：S1350524120001 gexingfu@huayuanstock.com 联系人 熊宇翔 xiongyuxiang@huayuanstock.com | 基本数据 | | | 年 | 08 月 | 25 | 日 | 2025 | | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | 103.25 | | | | 一 年 内 最 最 低 | 高 | / | | | | | | | （元） | | | | | | | | | 总市值（百万元） | | | | | 41,490.14 | | | | 流通市值（百万元） | | | | | 33,354.32 | | | | 总股本（百万股） | | | | | 401.84 | | | | 资产负债率（%） | | | | | 54.59 | | | | 每股净资产（元/股） | | | | | 11.49 | | | | 资料来源： ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The revenue from the DC transmission segment has significantly increased, with multiple ultra-high voltage projects expected to start within the year [5] - The company reported a 5.7% year-on-year decline in revenue for the first half of 2025, but a 0.96% increase in net profit attributable to shareholders [7] - The substantial growth in revenue from the DC transmission system, which saw a 212% year-on-year increase, has positively impacted the overall gross margin of the company [7] - The company is expected to benefit from the upcoming bidding for equipment related to newly approved ultra-high voltage DC projects in China [7] Financial Summary - For 2023, the company forecasts revenue of 17,061 million RMB, with a year-on-year growth rate of 14.37% [6] - The projected net profit attributable to shareholders for 2025 is 1,349 million RMB, reflecting a year-on-year growth of 20.75% [6] - The company's gross margin for the first half of 2025 reached 23.8%, an increase of 2.9 percentage points year-on-year [7] - The company’s total market capitalization is approximately 24,103.61 million RMB, with a circulating market value of 23,936.85 million RMB [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's main business of zippers shows steady growth, and the results of its globalization strategy are beginning to emerge [5] - The company focuses on sustainable development, transformation, and enhancing core competitiveness [7] - The company has achieved a revenue of 2.338 billion yuan in H1 2025, with a year-on-year growth of 1.80% despite external disturbances [7] Financial Performance Summary - Revenue forecast for 2023 to 2027 shows a growth trajectory from 3.907 billion yuan in 2023 to 6.008 billion yuan in 2027, with a CAGR of approximately 8.84% [6] - The net profit attributable to shareholders is projected to grow from 558 million yuan in 2023 to 934 million yuan in 2027, reflecting a growth rate of 12.31% in 2027 [6] - The company’s gross profit margin for H1 2025 is 42.89%, with a net profit margin of 15.80% [7] Product and Regional Performance - The zipper business generated revenue of 1.293 billion yuan in H1 2025, a year-on-year increase of 2.68%, accounting for 55.30% of total revenue [7] - International business revenue reached 864 million yuan in H1 2025, a year-on-year increase of 13.72%, with an international revenue share of 36.97% [7] - The company is expanding its global footprint with operational industrial parks in Bangladesh and Vietnam, aiming to become a "global, innovative accessory kingdom" [7] Profitability and Efficiency - The company’s return on equity (ROE) is projected to increase from 12.83% in 2023 to 19.65% in 2027 [6] - The company is enhancing operational efficiency through overseas capacity layout and product R&D [7] - The gross profit margin for the zipper and button businesses improved to 43.32% and 43.48% respectively in H1 2025 [7]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company achieved a year-on-year revenue growth of 11.32% in H1 2025, with total revenue reaching 390 million yuan and a net profit of 30.46 million yuan, reflecting a decline of 12.07% year-on-year [7] - The company’s gross profit margin was 20.9%, down by 1.5 percentage points year-on-year, with a net profit margin of 6.9%, down by 3.2 percentage points year-on-year [7] - The company’s overseas revenue grew by 19% year-on-year, while the domestic market saw a decline in certain product categories, prompting the launch of a new brand to target niche markets [5][7] Financial Performance Summary - In H1 2025, the company’s main grain product revenue increased by 40% to 59.46 million yuan, with a gross margin improvement of 5 percentage points [7] - The company’s revenue from meat jerky products was 220 million yuan, accounting for 57.75% of total revenue, with a gross margin of 23.4% [7] - The company’s revenue from canned products increased by 61.13% to 34.17 million yuan, while revenue from meat powder products decreased by 9.72% to 48.495 million yuan [7] - The company’s projected net profits for 2025-2027 are estimated at 81 million, 98 million, and 120 million yuan respectively, with corresponding P/E ratios of 29.7, 24.6, and 20.0 [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company's performance is under short-term pressure, awaiting the launch of new capacity and a recovery in demand [6] - The company is a leader in domestic chemical shipping, with a clear business model, and is expected to maintain rapid growth in performance from 2025 to 2027 due to continuous investment in foreign trade capacity [8] Summary by Sections Market Performance - As of August 25, 2025, the closing price is 15.42 CNY, with a total market value of 5,011.50 million CNY and a circulating market value of 4,317.60 million CNY [4] Financial Data - The company reported a revenue of 787 million CNY in the first half of 2025, a year-on-year increase of 1.99%, and a net profit attributable to shareholders of 136 million CNY, a decrease of 24.80% year-on-year [8] - In Q2 2025, the company achieved a revenue of 405 million CNY, a year-on-year increase of 4.82%, while the net profit attributable to shareholders was 62 million CNY, down 39.90% year-on-year [8] Earnings Forecast and Valuation - Revenue forecasts for 2025-2027 are 1,548 million CNY, 1,979 million CNY, and 2,339 million CNY, respectively, with growth rates of 2.22%, 27.78%, and 18.21% [7] - Net profit forecasts for the same period are 294 million CNY, 374 million CNY, and 448 million CNY, with growth rates of -16.17%, 27.33%, and 19.68% [7] - The current price-to-earnings ratio (P/E) for 2025-2027 is projected to be 17.06, 13.40, and 11.19, indicating a favorable valuation [7] Operational Insights - The company is accelerating its capacity construction, with 12 chemical tankers under construction, expected to contribute to incremental revenue from 2025 to 2027 [8] - The gross margin in Q2 2025 was approximately 26.82%, a decrease of 14.11 percentage points year-on-year, primarily due to weak domestic demand and falling freight rates [8]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - In the first half of 2025, the company achieved revenue of 162 million yuan, a year-on-year increase of 46%, and a net profit attributable to shareholders of 30.64 million yuan, a year-on-year increase of 12% [6] - The company is expanding into low-altitude economy, military, robotics, and aviation applications, which are expected to drive future growth [5][6] - The company has successfully entered the advanced intelligent factory list in Zhejiang Province and has obtained six new invention patents, enhancing its market competitiveness [6] Financial Performance - In 2025H1, the automotive window system revenue increased by 73% year-on-year, driven by the vehicle replacement policy boosting downstream demand [6] - The company’s precision transmission system, automotive window system, and automotive vision system achieved revenues of 52 million yuan (up 39% YoY), 53.61 million yuan (up 73% YoY), and 43.3 million yuan (up 30% YoY) respectively [6] - The overall revenue and profit growth in the first half of 2025 indicates a strong cash flow improvement, with operating cash flow net amounting to 52.79 million yuan, a year-on-year increase of 68% [6] Market Outlook - The company is expected to benefit from the ongoing growth in the automotive industry, with China's vehicle production and sales reaching 15.62 million and 15.65 million units respectively, representing year-on-year growth of 12.5% and 11.4% [6] - The company is actively developing high-precision components for flying cars and has received certification for military equipment quality management, indicating a strategic move into the military sector [6] Earnings Forecast - The forecasted net profit attributable to shareholders for 2025-2027 is 80 million yuan, 98 million yuan, and 129 million yuan respectively, corresponding to current price-to-earnings ratios of 24.4, 20.0, and 15.2 times [6]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company's revenue in the first half of 2025 increased by 49% year-on-year, driven by national subsidies, with a promising recovery in the consumer electronics sector and expected growth in AIoT and security [5][8] - The company achieved a revenue of 94.88 million yuan in H1 2025, with a gross margin of 61.29%, benefiting from the recovery trend in the domestic consumer electronics industry and increased direct sales channel investments [8] - R&D expenses increased by 178% year-on-year, reflecting the company's commitment to enhancing its technological capabilities in chip development and IoT [8] Financial Performance Summary - Revenue Forecast: - 2023: 117 million yuan - 2024: 159 million yuan (growth of 36.63%) - 2025E: 184 million yuan (growth of 15.75%) - 2026E: 213 million yuan (growth of 15.31%) - 2027E: 249 million yuan (growth of 17.03%) [7] - Net Profit Forecast: - 2023: 45 million yuan - 2024: 58 million yuan (growth of 28.17%) - 2025E: 64 million yuan (growth of 10.77%) - 2026E: 76 million yuan (growth of 18.51%) - 2027E: 89 million yuan (growth of 17.42%) [7] - Earnings Per Share (EPS) Forecast: - 2023: 0.30 yuan - 2024: 0.38 yuan - 2025E: 0.42 yuan - 2026E: 0.50 yuan - 2027E: 0.59 yuan [7] Market and Industry Insights - The company is positioned favorably in the electronic device security industry, with a focus on shareholder returns and a stable dividend distribution policy, maintaining a payout ratio exceeding 80% over the past three years [8] - The anticipated recovery in the consumer electronics market, along with supportive national policies, is expected to drive downstream demand growth [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report highlights that cost reduction and incremental growth are offsetting the decline in coal prices, leading to stable performance and potential for increased dividends [5] - The company reported a significant decrease in revenue and net profit for the first half of 2025, with revenue at 744.4 billion yuan, down 19.9% year-on-year, and net profit at 77.0 billion yuan, down 21.3% year-on-year [6] - The coal division's net profit decreased by 32.6% year-on-year due to falling coal prices, despite a slight increase in production and sales volume [6] - The company is expected to maintain a high proportion of long-term contracts, which stabilizes performance amid market fluctuations [7] Summary by Sections Financial Performance - In H1 2025, the company achieved a coal production of 67.34 million tons, a year-on-year increase of 1.3%, with sales volume also increasing by 1.4% [6] - The average selling price of self-produced coal was 470 yuan per ton, down 19.5% year-on-year [6] - The company managed to reduce its unit sales cost to 263 yuan per ton, a decrease of 10.2% year-on-year [6] Business Segments - The chemical business faced challenges due to maintenance of the olefin unit, but the decline in coal prices helped reduce costs for methanol and urea [6] - The company is progressing with new projects, including coal and electricity integration and renewable energy initiatives, which are expected to contribute to future growth [7] Profit Forecast and Valuation - The forecasted net profits for 2025-2027 are 15.4 billion, 16.8 billion, and 17.96 billion yuan respectively, with corresponding growth rates of -20.3%, +9.2%, and +6.8% [7] - The current price-to-earnings ratio is projected to be 10.6, 9.7, and 9.0 for the years 2025, 2026, and 2027 respectively [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's performance meets expectations, with a focus on acquiring an antibacterial peptide new drug to accelerate its innovation transformation [5] - The company reported a revenue of 1.512 billion yuan in the first half of 2025, a year-on-year increase of 10.67%, and a net profit attributable to shareholders of 291 million yuan, up 2.57% year-on-year [7] - The company is enhancing its innovative drug pipeline by acquiring the antibacterial peptide new drug JIJ02 gel, which is currently in clinical phase I [7] Financial Summary - Revenue forecast for 2023 to 2027 is as follows: 2,693 million yuan (2023), 2,931 million yuan (2024), 3,288 million yuan (2025E), 3,606 million yuan (2026E), and 3,945 million yuan (2027E) with corresponding growth rates of 15.75%, 8.85%, 12.19%, 9.67%, and 9.41% [6] - Net profit attributable to shareholders is projected to be 368 million yuan (2023), 512 million yuan (2024), 572 million yuan (2025E), 607 million yuan (2026E), and 687 million yuan (2027E) with growth rates of 36.54%, 39.13%, 11.55%, 6.16%, and 13.25% respectively [6] - Earnings per share (EPS) is expected to be 0.74 yuan (2023), 1.02 yuan (2024), 1.14 yuan (2025E), 1.21 yuan (2026E), and 1.37 yuan (2027E) [6]